Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(1 year, 5 months ago) | |
US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(11 months from now) | |
US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(8 months from now) | |
US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(1 year, 11 months from now) | |
US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(5 years from now) |
Horizant is owned by Azurity.
Horizant contains Gabapentin Enacarbil.
Horizant has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Horizant are:
Horizant was authorised for market use on 13 December, 2011.
Horizant is available in tablet, extended release;oral dosage forms.
Horizant can be used as management of postherpetic neuralgia (phn) in adults, treatment of moderate-to-severe primary restless leg syndrome in adults.
Drug patent challenges can be filed against Horizant from 07 April, 2015.
The generics of Horizant are possible to be released after 10 June, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
New Indication(I-652) | Jun 06, 2015 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL